COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Valuation Ratios Analysis including PE, PB, PS, EV/EBITDA. Analyze if 3349.T stock is undervalued compared to peers/competitors, industry and sector standards or based on Value Investing Principles.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Valuation Analysis - Compare Against 3141.T

Comparison against 3141.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.

Price-to-Earnings Ratio (P/E)

30.52

Increased from previous period

P/E above 1.5x 3141.T's 12.43. Jim Chanos would check for potential multiple compression risks.

Price-to-Sales Ratio (P/S)

2.64

Decreased from previous period

P/S 1.25-1.5x 3141.T's 1.77. Martin Whitman would scrutinize if premium reflects better growth prospects.

Price-to-Book Ratio (P/B)

2.81

Decreased from previous period

P/B 1.1-1.25x 3141.T's 2.40. Bill Ackman would demand evidence of superior asset utilization.

Price-to-Free Cash Flow Ratio

64.30

Decreased from previous period

P/FCF 1.25-1.5x 3141.T's 45.53. Martin Whitman would scrutinize if premium reflects better growth prospects.

Price-to-Operating Cash Flow Ratio

64.30

Decreased from previous period

P/OCF 1.25-1.5x 3141.T's 45.53. Martin Whitman would scrutinize if premium reflects better business model.

Price-to-Fair Value

2.81

Decreased from previous period

Fair value ratio 1.1-1.25x 3141.T's 2.40. Bill Ackman would demand evidence of superior economics.

Earnings Yield

0.82%

Decreased from previous period

Earnings yield below 50% of 3141.T's 2.01%. Michael Burry would check for earnings deterioration risks.

Free Cash Flow Yield

1.56%

Increased from previous period

FCF yield 50-75% of 3141.T's 2.20%. Martin Whitman would scrutinize if lower yield reflects better reinvestment.

Select Chart Metric:

3349.T Valuation Analysis - Compare Against 3141.T

Comparison against 3141.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Price-to-Earnings Ratio (P/E)

30.52

Increased from previous period

P/E above 1.5x 3141.T's 12.43. Jim Chanos would check for potential multiple compression risks.

Price-to-Sales Ratio (P/S)

2.64

Decreased from previous period

P/S 1.25-1.5x 3141.T's 1.77. Martin Whitman would scrutinize if premium reflects better growth prospects.

Price-to-Book Ratio (P/B)

2.81

Decreased from previous period

P/B 1.1-1.25x 3141.T's 2.40. Bill Ackman would demand evidence of superior asset utilization.

Price-to-Free Cash Flow Ratio

64.30

Decreased from previous period

P/FCF 1.25-1.5x 3141.T's 45.53. Martin Whitman would scrutinize if premium reflects better growth prospects.

Price-to-Operating Cash Flow Ratio

64.30

Decreased from previous period

P/OCF 1.25-1.5x 3141.T's 45.53. Martin Whitman would scrutinize if premium reflects better business model.

Price-to-Fair Value

2.81

Decreased from previous period

Fair value ratio 1.1-1.25x 3141.T's 2.40. Bill Ackman would demand evidence of superior economics.

Earnings Yield

0.82%

Decreased from previous period

Earnings yield below 50% of 3141.T's 2.01%. Michael Burry would check for earnings deterioration risks.

Free Cash Flow Yield

1.56%

Increased from previous period

FCF yield 50-75% of 3141.T's 2.20%. Martin Whitman would scrutinize if lower yield reflects better reinvestment.

Select Chart Metric: